Dysregulation of the Hh pathway observed in MB and other tumours can be caused by ligand-independent events, such as genetic mutations of pathway components (PTCH, SMO, SuFu, REN, GLI1/GLI2 amplification) [7,8] or ligand-dependent mechanisms of activation [9,10]. Here, GLI1 is linked to neoplasm.